1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Ascierto, P. A.; Melero, I.; Bhatia, S.; Bono, P.; Sanborn, R. E.; Lipson, E. J.; Callahan, M. K.; Gajewski, T.; Gomez-Roca, C. A.; Hodi, F. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages
    Meeting Abstract

    Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Ribas, A.; Brail, L.; Pearlberg, J.; Mahabhashyam, S.; Lee, L.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine and inhibition of the downstream AHR pathway
    Meeting Abstract

    McGovern, K.; Zhang, X. M.; Stone, E.; Triplett, T.; Garrison, K.; Coma, S.; Campesato, L. F.; Walsh, M.; Tchaicha, J.; Lamb, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Santomasso, B.; Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
    Meeting Abstract

    Zamarin, D.; Ricca, J.; Oseledchyk, A.; Gigoux, M.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Dissecting the mechanisms underlying antitumor effects of live oncolytic vaccinia and heat-inactivated vaccinia
    Meeting Abstract

    Wang, W.; Dai, P.; Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; Mangarin, L. M.; De Henau, O.; Budhu, S.; Li, Y.; Cortez, C.; Xia, Y.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Isoform specific TGF-β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy
    Meeting Abstract

    Gupta, A.; Budhu, S.; Giese, R.; van Snick, J.; Uyttenhove, C.; Ritter, G.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primates
    Meeting Abstract

    Gombos, R.; Gonzalez, A.; Manrique, M.; Chand, D.; Savitsky, D.; Morin, B.; Breous-Nystrom, E.; Dupont, C.; Ward, R.; Mundt, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • AGEN2034, a novel anti-PD-1 antibody that combines effectively with CTLA-4 pathway blockade to enhance T cell activity
    Meeting Abstract

    Chand, D.; Savitsky, D.; Gonzalez, A.; Clarke, C.; Schuster, A.; Drouin, E. E.; Waight, J. D.; Mundt, C.; Ritter, G.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save